Renal Flashcards
AKI
defined as an acute drop in kidney function (under 48 hours). It is diagnosed by measuring the serum creatinine.
AKI criteria
- Rise in creatinine of ≥ 26.4 micromol/L in 48 hours (>1.5-1.9 x reference) or <0.5ml/kg/hr for >6 hours
- Rise in creatinine of ≥ 50% (>2-2.9 x reference) in 7 days or Urine output of < 0.5ml/kg/hour for > 12 hours
- Increase >3 x reference SCr or increase to >354 and <0.3ml/Kg/hr for >24 hours
risk factors for AKI
- CKD
- Heart failure
- Diabetes
- Liver disease
- Previous AKI
- Peripheral vascular disease
- Older age (above 65 years)
- Cognitive impairment
- Nephrotoxic medications such as NSAIDS and ACE inhibitors
- Use of a contrast medium such as during CT scans
Pre-renal (inadequate supply of blood to kidneys reducing filtration of blood)
- Hypovolaemia: Haemorrhage, volume depletion (e.g. D&V, burns and dehydration)
- Hypotension: cardiogenic shock and distributive shock (sepsis or anaphylaxis)
- Renal Hypoperfusion: Heart failure, NSAIDs/ACEi/ARBs/hepatorenal syndrome
Renal causes of AKI
- Glomerulonephritis
- Interstitial nephritis: Drugs (NSAIDs, antibiotics, PPI), Infection (TB) and systemic (sarcoidosis)
- Tubular injury: Ischaemia, drugs (gentamicin), contrast and rhabdomyolysis
- Acute tubular necrosis
- Vasculitis/renovascular
Post renal causes (obstruction to outflow of urine from the kidney, causing back-pressure into the kidney and reduced kidney function)
- Kidney stones
- Ureter or urethral strictures
- Enlarged prostate or prostate cancer
- Masses such as cancer in the abdomen or pelvis
sign/symptoms of AKI
- Constitutional symptoms e.g. Anorexia, weight loss, fatigue, lethargy
- Nausea & Vomiting
- Itch
- Fluid overload: Oedema, SOB
Signs
- Fluid overload incl hypertension, Oedema, Pul oedema, effusions (pleural & pulmonary)
- Uraemia incl itch, pericarditis
- Oliguria
AKI Iv
Urinalysis: protein, blood, nitrites, glucose, WCC
U&E
FBC and coagulation screen
immunology: ANA, ANCA, GBM
protein electrophoresis and BJP
USS
biopsy
Management of AKI
- assess for hydration: BP, HR, UO, JVP, CRT, Oedema
- IV Fluid hydration (fluid challenge for hypovolaemia) - crystalloid (0.9% NaCl) or colloid: not 5% dextrose
- bolus of fluid, if >1000mls and no improvement, seek help
- heart failure: fluid overload be careful - Stop nephrotoxic medications e.g. NSAIDS and ACEi
- Relive obstruction in post renal AKI
- Dialysis: anuria or uraemia
AKI complications
Hyperkalaemia
fluid overload, heart failure and pulmonary oedema
metabolic acidosis, uraemia (encephalopathy or pericarditis)
CKD
abnormal kidney function and/or structure
CKD risk factor
AKI CVD disease diabetes hypertension Glomerulonephritis Polycystic kidney disease age related decline Medication: NSAIDs, ACEi/ARBs and lithium Smoking Untreated urinary outflow tract obstruction proteinuria
CKD Iv
U&Es and eGFR (2 tests + 3 months apart)
Proteinuria (ACR) and Haematuria (dipstick)
renal USS
ACR stages
A1: <3
A2: 3-30
A3: >30
CKD stages
G1: >90 G2: 60-89 G3a: 45-59 G3b: 30-44 G4: 15-29 G5: <15`
Accelerated CKD
sustained decrease in GFR of 25% or more and a change in GFR category within 12 months
Or
a sustained decrease in GFR of 15 ml/min/1.73m2 per year
Renal consequences of CKD
- Local – pain/ haemorrhage/ infection
- Urinary – haematuria/ proteinuria
- Impaired salt and water handling
- Hypertension
- Electrolyte abnormalities
- Acid-base disturbance → ESRD (End stage renal disease)
slowing CKD management
- ACEi - Reduce proteinuria
- Treat glomerulonephritis
- Exercise, maintain a healthy weight and stop smoking
- Special dietary advice about phosphate, sodium, potassium and water intake
- Offer atorvastatin 20mg
Anaemia of CKD
Target 100-120Hb, exclude B12 and folate, check ferritin (>100) and TSats > 20%
- Oral iron - IV iron - EPO
Bone disease of CKD
- Osteomalacia occurs due to increased turnover of bones without adequate calcium supply.
Osteosclerosis occurs when the osteoblasts respond by increasing their activity to match the osteoclasts by creating new tissue in the bone, however due to the low calcium level this new tissue is not properly mineralised. - Osteoporosis can exist alongside the renal bone disease due to other risk factors such as age and use of steroids.
CKD: Bone disease management
- Active forms of vitamin D (alfacalcidol and calcitriol) – don’t need activation by kidneys
- Phosphate binders
- Salt reduction, K+ and fluid restriction
- Bisphosphonates
Dialysis 3 main purposes
excess fluid, solutes and waste products.
Dialysis based on
- Diffusion e.g. urea, K+, Na+ and infusion of HCO3-
- Convection: water across semipermeable membrane
- Adsorption: atoms, ions or molecules from a substance
adhere to a surface of the adsorbent
e.g. plasma proteins
Dialysis indications
A – Acidosis (severe and not responding to treatment)
E – Electrolyte abnormalities (severe and unresponsive hyperkalaemia)
I – Intoxication (overdose of certain medications)
O – Oedema (severe and unresponsive pulmonary oedema)
U – Uraemia symptoms such as seizures or reduced consciousness
eGFR < 7ml/min
Haemodiafiltration (HDF)
haemodialysis is primarily diffusive, haemodiafiltration is increasingly convective, in nature. greater the convective force, the greater will be the generated volume of the pressure-driven ‘ultrafiltrate’. • Large volumes of ultrafiltrate add enormously to solute drag - especially for the larger “middle molecule” solute classes
different types of PD
continuous (2L x 4times per day) vs automated (overnight)
types of renal transplant
Deceased Heart Beating Donors (Brain stem death (DBD))
Non-Heart Beating Donors (DCD)
Live Donation (altruistic)
Lifelong immunosuppression for kidney transplant
Induction
Consolidation
Maintenance
Transplant rejection types
- Hyperacute - preformed antibodies
- Acute rejection: cellular or antibody mediated, treated with immunosuppression
- Chronic rejection: antibody mediated slowly progressive decline in renal function.
CMV infection - transplant
1st 3 months
- Prophylactic PO valganciclovir in higher risk patients
- IV ganciclovir if evidence of infection
Nephritic syndrome
Haematuria oliguria Proteinuria (<3g) Oedema Hypertension affect endothelial cells (proliferative process)
Nephrotic syndrome
Peripheral oedema Proteinuria >3g Hypoalbuminemia (<25g/L) Hypercholesterolaemia affects podocytes (non-proliferative process)
Minimal change disease
usually idiopathic, most common nephrotic syndrome in children, secondary to hodgkins lymphoma, leukaemia and a virus
EM: foot fusion
1st line: steroids
2nd line: cyclophosphamide
Focal segmental glomerulosclerosis
small sections of each glomerulus (filter), and only a limited number of glomeruli are damaged at first.
Commonest cause of nephrotic syndrome in adults (35%)
primary (more common) or secondary (HIV/Heroin use/Obesity/ Reflux nephropathy)
Focal segmental glomerulosclerosis diagnosis and management
Small areas of mesangial collapse and sclerosis
steroids
Membranous glomerulonephritis
2nd commonest cause of nephrotic syndrome in adults (15-30%)
- idiopathic (majority)
- Infections (Hep B), malignancies, Connective tissue diseases and drugs (gold/penicillamine)
Membranous glomerulonephritis diagnosis
Renal biopsy: subepithelial immune complex deposition in the basement membrane
Anti PLA2r antibody: forms immune complex stuck between podocytes and basement membrane (blood)
LM: Diffuse thickening of GBM. “spikes” with special silver stains
IF: “IgG and complement (C3) deposits on the basement membrane”
EM: Electron dense sub-epithelial deposits
Membranous glomerulonephritis Mx
immunosuppression e.g. Steroids/Alkylating agents/B cell monoclonal Ab (rituximab: stop antibody production and therefore damage)
• 30% progress to end stage renal failure in 10 years
IgA nephropathy
Commonest GN in the world (Nephritis)
IgA nephropathy signs/symptoms
Asymptomatic microhaematuria non-nephrotic range proteinuria
Macroscopic haematuria after resp/GI infection
Young adult and tonsillitis
AKI (red cells clogging tubes up)/CKD
Associated with Henoch-Schonlein Purpura (HSP) (arthritis/colitis/ purpuric skin rash)
IgA nephropathy Ix and management
LM: Diffuse mesangial IgA deposition
IF: IgA and C3 deposition
EM: Electron dense deposits in mesangium
- BP control/ ACE inhibitors & ARBs/ Fish oil
- Corticosteroids if persistent proteinuria >1g 3-6 months of ACE-i/ARB and GFR>50
Post streptococcal glomerulonephritis (AKA diffuse proliferative glomerulonephritis)
Skin or throat infection: 1-3 weeks after a streptococcal infection (e.g. tonsillitis or impetigo)
Strep endocarditis: immune complex (bacterial antigen and antibody) – circulates and lodges into the kidney
They develop a nephritic syndrome
Can cause rapid decline unlike IgA
Complement levels are lower in this but normal in IgA nephropathy
Post streptococcal glomerulonephritis Ix
Evidence of strep infection: increase ASOT, anti-DNAse B or decrease C3
CRP (less in IgA) and more in raise in this
Fever, AKI, CRP, low complement
Echo: for endocarditis
Mesangiocapillary glomerulonephritis
Idiopathic
Secondary to Autoimmune e.g. SLE, RA, Cancer
Mixed nephrotic/ nephritic syndrome
Mesangiocapillary glomerulonephritis diagnosis
LM: Mesangial proliferation, neutrophils and monocytes, thickened capillary walls. “tram track” GBM
IF: Granular deposits of C3
EM: Electron dense sub-endothelial deposits +/- sub-epithelial +/- mesangial
Mesangiocapillary glomerulonephritis management
ACE-i/ARB and BP control
Treat underlying cause
Trial of immunosuppression if no underlying cause is found and progressive decline in function
Rapidly progressive glomerulonephritis
ANCA-Positive: Systemic Vasculitis, Wegener’s granulomatosis (Granulomatosis with polyangiitis) and Microscopic polyangiitis
ANCA-Negative: Goodpasture’s disease-Anti-GBM, Henoch Scholein Purpura HSP/IgA, IgA & membranous (transforms into this) and Systemic Lupus Erythematosus SLE
crescentic glomerulonephritis
Rapidly progressive glomerulonephritis signs/symptoms
Rapid deterioration in renal function over days/weeks
Active urinary sediment (RBC’s, RBC & Granular Casts)
It presents with a very acute illness with sick patients but it responds well to treatment
Rapidly progressive glomerulonephritis management
• Immunosuppression
- Steroids (IV Methylprednisolone / Oral Prednisolone)
- Cytotoxic (Cyclophosphamide/ Mycophenolate/ Azathioprine
- dialysis
Goodpasture Syndrome
Anti-GBM (glomerular basement membrane) antibodies attack glomerulus and pulmonary basement membranes due to type IV collagen
Goodpasture Syndrome Mx
Imunosuppression
- Steroids (IV Methylprednisolone / Oral Prednisolone)
- Cytotoxic (Cyclophosphamide/ Mycophenolate/ Azathioprine
- dialysis
Diabetic nephropathy
chronic high level of glucose passing through the glomerulus causes scarring. This is called glomerulosclerosis. Haemodynamic changes – increased GFR and initial decrease in creatinine – afferent arteriolar vasodilation mediated by range of vasoactive mediators.
Renal hypertrophy due to raised plasma glucose which stimulates growth factors, renin-angiotensin aldosterone activation, production of advanced glycation products and oxidative stress
Diabetic nephropathy screening
albumin: creatinine ratio and U&Es.
Overt diabetic nephropathy is characterised by persistent albuminuria
(300mg/24 hours on at least 2 occasions separated by 3-6 months)
Diabetic nephropathy management
optimising blood sugar levels (Hb1Ac below 53 mmol to reduce microvascular complications) and blood pressure (ACE inhibitors)
Lipid control: statins
Myeloma
Cancer of plasma cells: a type of WBC normally responsible for producing antibodies
Excess production of immunoglobins (proteins)
Collections of abnormal plasma cells accumulate in the bone marrow
Myeloma diagnosis
FBC, U&Es, LFTS
Bloods: Serum Protein Electrophoresis and Serum Free light chains
Urine: Bence Jones Protein
Bone Marrow Biopsy
Myeloma management
Stop nephrotoxic medication e.g. NSAIDs – don’t give for the back pain
Diuretics in view of risk increasing cast formation – flush calcium out as well
Manage hypercalcaemia (saline +/- bisphosphonates [inhibit osteoclasts] )
- Chemotherapy to reduce tumour load
- High dose dexamethasone may help reduce tumour load
- Thalidomide/bortezomib: monoclonal antibodies
- Stem cell transplant
Amyloidosis
extracellular amyloid (insoluble protein fibrils) in tissues or organs
Occurs due to abnormal folding of proteins which aggregate and become insoluble
Amyloidosis types
- Primary / Light chain (AL)
- Secondary / Systemic / Inflammatory (AA)
- Dialysis (Aβ2M)
- Hereditary and old age (ATTR)
Amyloidosis complications
Renal – (nephrotic range) proteinuria +/- impaired renal function
Cardiac – Restrictive Cardiomyopathy
Nerves – peripheral or autonomic neuropathy
Hepatomegaly / Splenomegaly
GI – malabsorption
Amyloidosis Iv
Urinalysis + uPCR (urine protein creatinine ratio)
Blood tests – renal function, markers of inflammation, protein electrophoresis, SFLC (Serum free light-chain measurement)
Renal Biopsy: Congo red staining (apple green under polarised light)
[Other biopsy - abdominal fat pad or rectal biopsy]
SAP scan – Scintigraphy with radiolabelled serum amyloid – shows extent of disease
Vasculitis Mx
Corticosteroids
Cyclophosphamide/Rituximab
Azathioprine/Methotrexate used for maintenance
Plasma Exchange – dialysis machine
SLE diagnosis
High index of suspicion: young lady with non-specific symptoms
Blood: Raised inflammatory markers, Immunology – ANA +ve, anti-dsDNA ab (~70%) and Complement – low levels
Urinalysis: protein: ACR >30 and PCR>50
Renal biopsy:
Interstitial nephritis
inflammation of the space between cells and tubules (the interstitium) within the kidney.
Acute interstitial nephritis
presents with AKI and hypertension
acute inflammation of tubules and interstitium
hypersensitivity reaction to:
- drugs (NSAIDs or antibiotics)
- Infection e.g. strep
- autoimmune
Acute interstitial nephritis other signs/symptoms
o Rash o Fever o Eosinophilia on blood test o Arthralgia AKI + hypertension
Acute interstitial nephritis management
treat underlying cause
steroids
Chronic Tubulointerstitial Nephritis
chronic inflammation of the tubules and interstitium. Presents as CKD.
Autoimmune, infectious, iatrogenic and granulomatous disease causes
Chronic Tubulointerstitial Nephritis management
ACEi/ARB (BP control), glucose control and lipids (statins)
steroids